1. Home
  2. SPRO vs FCAP Comparison

SPRO vs FCAP Comparison

Compare SPRO & FCAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.28

Market Cap

136.7M

Sector

Health Care

ML Signal

HOLD

Logo First Capital Inc.

FCAP

First Capital Inc.

N/A

Current Price

$58.75

Market Cap

125.9M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
SPRO
FCAP
Founded
2013
1891
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Savings Institutions
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
136.7M
125.9M
IPO Year
2017
1999

Fundamental Metrics

Financial Performance
Metric
SPRO
FCAP
Price
$2.28
$58.75
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$5.00
N/A
AVG Volume (30 Days)
281.7K
24.4K
Earning Date
11-13-2025
01-23-2026
Dividend Yield
N/A
2.04%
EPS Growth
N/A
25.19
EPS
N/A
4.41
Revenue
$40,549,000.00
$47,323,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$13.78
Revenue Growth
N/A
15.22
52 Week Low
$0.51
$30.49
52 Week High
$3.22
$71.00

Technical Indicators

Market Signals
Indicator
SPRO
FCAP
Relative Strength Index (RSI) 45.17 52.99
Support Level $2.26 $59.76
Resistance Level $2.37 $61.48
Average True Range (ATR) 0.07 3.52
MACD -0.00 -0.99
Stochastic Oscillator 12.12 15.22

Price Performance

Historical Comparison
SPRO
FCAP

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About FCAP First Capital Inc.

First Capital Inc is the financial holding company of First Harrison Bank. Through its subsidiary, it operates as a federally-chartered savings bank that provides banking services to individuals and business customers across locations in America. The bank offers various loans which include residential loans, construction loans, commercial real estate loans and commercial business loans. It also provides consumer loans such as home equity and second mortgage loans, and automobile and truck loans.

Share on Social Networks: